Treatment challenges in axial spondylarthritis and future directions

Current Rheumatology Reports

Volumn 15, Issue 9, 2013, Pages

  Sieper, Joachim ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Axial spondyloarthritis; Non TNF blocker biologics; NSAIDs; Optimizing treatment strategies; Radiographic progression; Remission; Seronegative arthritis; TNFblocker; Treatment; Treatment challenges

Indexed keywords

ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA;

DISEASE COURSE; DRUG ANTAGONISM; HUMAN; PROGNOSIS; RADIOGRAPHY; REVIEW; SPONDYLARTHRITIS; TREATMENT FAILURE; ANTAGONISTS AND INHIBITORS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; BIOLOGICAL PRODUCTS; DISEASE PROGRESSION; HUMANS; PROGNOSIS; SPONDYLARTHRITIS; TREATMENT FAILURE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84880347482     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-013-0356-9     Document Type: Article

References (51)

1. Rudwaleit M, Van Der Heijde D, Landewe R, Listing J, Akkoc N,Brandt J, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68(6):777-83. Epub 2009/03/20.
2. Braun J, Van Den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011;70(6):896-904.
3. Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis. 2004;63(6):665-70. (Pubitemid 38658395)
4. RudwaleitM, Schwarzlose S, Hilgert ES, Listing J, Braun J, Sieper J. MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis. 2008;67(9):1276-81. Epub 2007/11/17.
5. Barkham N, Keen HI, Coates LC, O'Connor P, Hensor EMA, Fraser A, et al. Clinical response and time to active disease following infliximab therapy in patients with HLA-B27 positive very early ankylosing spondylitis. Ann Rheum Dis. 2009;68(Suppl3):72.
6. Song IH, Hermann K, Haibel H, Althoff C, Listing J, Burmester G, et al. Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. Ann Rheum Dis. 2011;70(4):590-6. Epub 2011/ 03/05.
7. Van Der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebocontrolled trial (ASSERT). Arthritis Rheum. 2005;52(2):582-91. Epub 2005/02/05. (Pubitemid 40216323)
8. Haibel H, Rudwaleit M, Listing J, Heldmann F, Wong RL, Kupper H, et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebocontrolled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum. 2008;58(7):1981-91. Epub 2008/06/ 26. (Pubitemid 351988090)
9. Sieper J, Van Der HeijdeD,Dougados M, Mease PJ, Maksymowych WP, Brown MA, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis. 2013;72(6):815-22. Epub 2012/07/10. First phase III trial of a TNFblokcer in non-radiographic axial SpA resulting in the approval for adalimumab in the EC for this indication.
10. Van Der Heijde D, Sieper J, Maksymowych WP, Dougados M, Burgos-Vargas R, Landewe R, et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis. 2011;70(6):905-8. Epub 2011/05/05.
11. Sieper J, Lenaerts J, Wollenhaupt J, Rudwaleit M, Mazurov VI, Myasoutova L, et al. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1. Ann Rheum Dis. 2013. Epub 2013/05/23. In this trial, it was shown that a combination of a TNF-blocker plus an NSAID in early axSpA patients who are not yet NDAIDs failures results in a high remission rate, but remission was also achieved in 35% in the NSAIDs alone group, further stressing the importance of early diagnosis and early treatment.
12. Jarrett SJ, Sivera F, Cawkwell LS, Marzo-Ortega H, McGonagle D, Hensor E, et al.MRI and clinical findings in patients with ankylosing spondylitis eligible for anti-tumour necrosis factor therapy after ashort course of etoricoxib. Ann Rheum Dis. 2009;68(9):1466-9.Epub 2008/10/28.
13. Barkhuizen A, Steinfeld S, Robbins J, West C, Coombs J, Zwillich S. Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis. J Rheumatol. 2006;33(9):1805-12. Epub 2006/09/09.
14. Sieper J, Van Der Heijde D. Review: Nonradiographic axial spondyloarthritis: new definition of an old disease? Arthritis Rheum. 2013;65(3):543-51. Epub 2012/12/13. Important review on the current eveidence about non-radioagraphic axSpA.
15. Van Der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, doubleblind, placebo-controlled trial. Arthritis Rheum. 2006;54(7):2136-46. Epub 2006/06/28. (Pubitemid 44051069)
16. Song IH, Weiss A, Hermann KG, Haibel H, Althoff CE, Poddubnyy D, et al. Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1 year of treatment with etanercept: results from the ESTHERtrial. Ann Rheum Dis. 2013;72(6):823-5.Epub 2012/11/23. First trial showing a similar response rate of active patients with non-radiographic axSpA and ankylosing spondylitis if treated with a TNF-blocker.
17. Landewe R, Rudwaleit M, Van Der Heijde D, Dougados M, Maksymowych W, Braun J, et al. Effect of Certolizumab Pegol On Signs and Symptoms of Ankylosing Spondyltitis and Non-Radiographic Axial Spondyloarthritis: 24 Week Re- sults of a Double Blind Randomized Placebo-Controlled Phase 3 Axial Spondyloarthritis Study. Arthritis Rheum. 2012;64:S336.
18. Poddubnyy D, Rudwaleit M, Haibel H, Listing J, Marker-Hermann E, Zeidler H, et al. Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Ann Rheum Dis. 2011;70(8):1369-74. Epub 2011/05/31.
19. Smolen J, Braun J, Dougados M, Emery P, FitzGerald O, Helliwell P, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis. 2013. Epub 2013/06/08.
20. Schipper LG, Vermeer M, Kuper HH, Hoekstra MO, Haagsma CJ, Den Broeder AA, et al. A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usualcare treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry. Ann Rheum Dis. 2012;71(6):845-50. Epub 2012/01/03.
21. Baraliakos X, Listing J, Rudwaleit M, Brandt J, Alten R, Burmester G, et al. Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosingspondylitis. J Rheumatol. 2007;34(3):510-5. (Pubitemid 46364005)
22. Song IH, Althoff CE, Haibel H, Hermann KG, Poddubnyy D,Listing J, et al. Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial. Ann Rheum Dis. 2012;71(7):1212-5. Epub 2012/03/24.
23. Haibel H, Heldmann F, Listing J, Kupper H, Braun J, Sieper J. Long-term efficacy of adalimumab after drug withdrawal and retreatment of flare patients in active non-radiographic, axial spondyloarthritis. Arthritis Rheum. 2013. Epub 2013/05/21.
24. Smolen JS, Nash P, Durez P, Hall S, Ilivanova E, Irazoque-Palazuelos F, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet. 2013;381(9870):918-29. Epub 2013/01/22.
25. Navarro-Compan V, Moreira V, Ariza-Ariza R, Hernandez-Cruz B, Vargas-Lebron C, Navarro-Sarabia F. Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease. Clin Rheumatol. 2011;30(7):993-6. Epub 2011/03/05. Interesting study showing that remission can be maintained in AS in a substantial proportion of patients if the TNFblocker dose is decreased.
26. Sieper J, Van Der Heijde D, Dougados M, Brown LS, Lavie F, Pangan AL. Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis. Ann Rheum Dis. 2012;71(5):700-6. Epub 2011/12/01.
27. Vincent FB, Morand EF, Murphy K, Mackay F, Mariette X, Marcelli C. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis. 2013;72(2):165- 78. Epub 2012/11/28.
28. Lie E, Van Der Heijde D, Uhlig T, Mikkelsen K, Rodevand E, Koldingsnes W, et al. Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register. Ann Rheum Dis. 2011;70(1):157-63. Epub 2010/11/11.
29. Rudwaleit M, Van Den Bosch F, Kron M, Kary S, Kupper H. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. Arthritis Res Ther. 2010;12(3):R117. Epub 2010/06/18.
30. Breban M, Ravaud P, Claudepierre P, Baron G, Henry YD, HudryC, et al. Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. Arthritis Rheum. 2008;58(1):88-97. Epub 2008/01/01.
31. Li EK, Griffith JF, Lee VW,Wang YX, Li TK, Lee KK, et al. Shortterm efficacy of combination methotrexate and infliximab in patients with ankylosing spondylitis: a clinical and magnetic resonance imaging correlation. Rheumatology (Oxford). 2008;47(9):1358-63.Epub 2008/06/25.
32. Heiberg MS, KoldingsnesW, Mikkelsen K, Rodevand E, Kaufmann C, Mowinckel P, et al. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum. 2008;59(2):234-40. Epub 2008/02/02. (Pubitemid 351272960)
33. Haibel H, Rudwaleit M, Listing J, Sieper J. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis. 2005;64(2):296-8.
34. Song IH, Heldmann F, Rudwaleit M, Haibel H, Weiss A, Braun J, et al. Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Ann Rheum Dis. 2011. Epub 2011/03/19.
35. Sieper J, Porter-Brown B, Thompson L, Harari O, Dougados M. Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Ann Rheum Dis. 2013. Epub 2013/06/15. Important doubleblin placebo-controlled trial showing that the IL-6 receptor anatgonist tocilizumab is not effective against ankylosing spondylitis.
36. Sieper J, Inman R, Badalamenti S, Radin A, Braun J. Sarilumab for the treatment of ankylosing spondylitis: results of a phase 2, randomized. Double-blind, placebo-controlled, international study (align). Ann Rheum Dis. 2012;71(Suppl3):111
37. Song IH, Heldmann F, Rudwaleit M, Listing J, Appel H, Braun J, et al. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum. 2010;62(5):1290- 7. Epub 2010/05/13.
38. Song IH, Heldmann F, RudwaleitM, Listing J, Appel H, Haug-Rost I, et al. One-year follow-up of ankylosing spondylitis patients responding to rituximab treatment and re-treated in case of a flare. Ann Rheum Dis. 2013;72(2):305-6. Epub 2012/08/14.
39. Sherlock JP, Joyce-Shaikh B, Turner SP, Chao CC, Sathe M, Grein J, et al. IL-23 induces spondyloarthropathy by acting on ROR-gammat+CD3+CD4-CD8- entheseal resident T cells. Nature medicine. 2012;18(7):1069-76. Epub 2012/07/10. Very interesting data raised in an animal model suggesting that IL-23 might be an important cytokine in the pathogenesis of spondyloarthritis which might be responsible both for inflammation and new bone formation.
40. Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010;362(2):118-28. Epub 2010/01/15.
41. Baeten D, Baraliakos X, Brauer J, Sieper J, Emery P, Van Der Heijde D, et al. Anti-Interleukin-17A Monoclonal Antibody Secukinumab in Ankylosing Spondylitis: A Randomized, Double-Blind, Placebo-Controlled Trial. The Lancet. 2013;in press. Small placebo-controlled trial indicating that inhibition of IL-17 might be effective in the treatment of ankylosing spondylitis.
42. Van Der Heijde D, Landewe R, Baraliakos X, Houben H, van Tubergen A, Williamson P, et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum. 2008;58(10):3063-70. Epub 2008/09/30.
43. Sieper J, Appel H, Braun J, Rudwaleit M. Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes. Arthritis Rheum. 2008;58(3):649- 56. Epub 2008/03/04. (Pubitemid 351364862)
44. Maksymowych WP, Morency N, Conner-Spady B, Lambert RG. Suppression of inflammation and effects on new bone formation in ankylosing spondylitis: evidence for a window of opportunity in disease modification. Ann Rheum Dis. 2013;72(1):23-8. Epub 2012/05/09.
45. Song IH, Hermann KG, Haibel H, Althoff CE, Poddubnyy D, Listing J, et al. Relationship between active inflammatory lesions in the spine and sacroiliac joints and new development of chroniclesions on whole-bodyMRI in early axial spondyloarthritis: results of the ESTHER trial at week 48. Ann RheumDis. 2011;70(7):1257-63.
46. Baraliakos X, Haibel H, Listing J, Sieper J, Braun J. Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. Ann Rheum Dis. 2013. Epub 2013/03/19. This study suggests that inhibition of new bone formation in ankylosing spondylitis patients might only be effective after 4 years of continuous TNF-blocker treatment.
47. Wanders A, Heijde D, Landewe R, Behier JM, Calin A, Olivieri I, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 2005;52(6):1756-65. (Pubitemid 40852884)
48. Poddubnyy D, Haibel H, Listing J, Marker-Hermann E, Zeidler H, Braun J, et al. Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum. 2012;64(5):1388-98. Epub 2011/12/01.
49. Kroon F, Landewe R, Dougados M, Van Der Heijde D. Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Ann Rheum Dis. 2012;71(10):1623-9. Epub 2012/04/26. Important study showing that NSAIDs have an inhibitory effect on new bone formation in anklyosing sppondylitis patients but only in those who are CRP-positive.
50. Dougados M, Simon P, Braun J, Burgos-Vargas R, Maksymowych WP, Sieper J, et al. ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis. Ann Rheum Dis. 2011;70(2):249-51. Epub 2010/09/11.
51. Poddubnyy D, Rudwaleit M, Haibel H, Listing J, Marker-HermannE, Zeidler H, et al. Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis. 2012;71(10):1616-22. Epub 2012/03/31.